UNSPSC 51284717: Azamulin

This classification denotes an antimicrobial with the molecular formula C24H38N4O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 875AQ866X1, chemically known as ((5-amino-s-triazol-3-yl)thio)acetic acid, 8-ester with (3as,4r,5s,6r,8r,9ar,10r)-6-ethyloctahydro-5,8-dihydroxy-4,6,9,10-tetramethyl-3a,9-propano-3ah-cyclopentacycloocten-1(4h)-one but more generally known as azamulin, which bears US NIH Compound Identifier 3086060.

UNSPSC 51284717 Azamulin is a Commodity code that encompasses pharmaceutical products and medications procured by state and local health agencies, community health departments, and first responder organizations. State and local governments buy actual pharmaceutical supplies and medical consumables under this code—naloxone and drug deactivation systems for public health initiatives, generic pharmaceuticals for state benefit programs, and medical and first aid supplies for emergency response divisions. The issuing-body mix includes state health agencies (Texas Health and Human Services Commission), county health departments (Seminole County), municipalities (City of Tampa), and state-administered cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). These entities procure through traditional competitive bidding (IFB), requests for information (RFI), and requests for proposal (RFP) mechanisms, often with multi-year award terms and renewal options.

Recent activity spans Florida, Texas, and Minnesota, with MMCAP's multistate cooperative purchasing vehicle serving participating jurisdictions across multiple states including Oregon. Representative recent opportunities include Seminole County, Florida's IFB 60459723LAS for 1,900 units of naloxone and 800 safe drug deactivation systems annually (response deadline July 26, 2023), the City of Tampa's IFB 26P00145 for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division with an estimated contract value of $700,000 and a sheltered-market set-aside for certified Small Local Business Enterprises (response deadline March 13, 2026), and MMCAP's RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026. The Texas HHS RFI HHS0017013 (posted April 3, 2026) signals emerging demand for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels, indicating potential future procurement expansion in prescription fulfillment and cost management.